Anti-GBM & Goodpasture’s
Organization & Website Links
News Articles & Media
- Treatment of anti-GBM antibody (Goodpasture’s) disease; UpToDate; January 12, 2016
- Rituximab in anti-GBM disease: A retrospective study of 8 patients; PubMed0MEDLINE, 2015
- Anti-GBM Antibody Disease; Medscape; May 28, 2014
- Anti-Glomerular Basement Membrane; Healthline, Karla Blocka, August 15, 2012
Anti–glomerular basement membrane (anti-GBM) antibody disease is a rare autoimmune disorder in which circulating antibodies are directed against an antigen normally present in the GBM and alveolar basement membrane. The resultant clinical syndrome encompasses a spectrum ranging from mild or no renal involvement to rapidly progressive glomerulonephritis. Many patients develop pulmonary hemorrhage, and most individuals have signs of a generalized systemic illness.
Glomerulonephritis due to Anti-GBM antibody disease is rare. It occurs in less than 1 case per million persons.
Treatment & Prognosis
Treatment of anti-GBM disease is focused on removing the anti-GBM antibody from the blood. Although disease eradication is likely, it commonly results in permanent kidney damage, and the eventual need for a transplant. Before receiving a kidney transplant, it is recommended that patients wait at least 6 months after finishing treatment for anti-GBM disease. Once it is sure that the disease is no longer active, transplant is very safe. The chance that the anti-GBM disease will come back in the kidney occurs in less than 5% of patients.
Of those diagnosed with anti-GBM present with both kidney and lung involvement
World Disease Maps
Add your name to the map and/or become a local ambassador.
Follow When Pigs Take Flight